Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 30Cr
-1.23%-1.91%+0.98%+17.94% 4.98TCr
-1.11%-2.84%+420.04%+505.15% 4.41TCr
-0.21%+0.37%+36.88%+17.32% 4.3TCr
-1.95%-3.33%+8.29%+73.25% 4.09TCr
-0.94%-1.77%+18.34%+46.84% 3.31TCr
-1.11%-4.20%+25.49%+119.78% 1.66TCr
+6.10%+4.40% - - 1.73TCr
+0.25%-0.98%+11.91%+27.62% 1.46TCr
-1.12%-3.46%+76.50%+39.37% 1.38TCr
Average +0.43%-1.79%+74.80%+105.91% 3.03TCr
Weighted average by Cap. -0.56%-1.57%+88.88%+122.63%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-